Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer
- Authors
- Thi My Hien Nguyen; Shin, In-Whoan; Lee, Tae Jin; Park, Junsoo; Kim, Jae Hyung; Park, Mi Sun; Lee, Eun-Ju
- Issue Date
- Mar-2016
- Publisher
- ACADEMIC PRESS INC ELSEVIER SCIENCE
- Keywords
- ITM2A; Ovarian cancer; Cell cycle; Tumor suppressor; Prognosis
- Citation
- GYNECOLOGIC ONCOLOGY, v.140, no.3, pp 545 - 553
- Pages
- 9
- Journal Title
- GYNECOLOGIC ONCOLOGY
- Volume
- 140
- Number
- 3
- Start Page
- 545
- End Page
- 553
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/7197
- DOI
- 10.1016/j.ygyno.2015.12.006
- ISSN
- 0090-8258
1095-6859
- Abstract
- Objective. Integral membrane protein 2A (ITM2A) is a type 2 transmembrane protein of unknown function. The aim of this study was to investigate its expression pattern, clinical significance, and biological function in epithelial ovarian cancer. Methods. ITM2A expression in 35 normal, 20 adenoma, 11 borderline and 90 cancerous ovarian tissues was measured by immunohistochemistry. Clinicopathological parameters were obtained from medical records. Survival data was analyzed using Kaplan-Meier estimates and multivariate analysis using the Cox-regression method. Anti-tumor activities of ITM2A were explored by cell proliferation and colony formation assays, flow cytometry, Western blots and animal studies using ovarian cancer cell lines. Chemoresponsiveness was evaluated by measuring IC50 and confirmed by animal studies using an intraperitoneal orthotropic model. Results. ITM2A was significantly downregulated in invasive carcinomas compared to normal, adenoma and borderline tumor tissues. ITM2A loss occurred in 45.6% (41 of 90) of invasive carcinomas and was significantly associated with FIGO stage, type II tumors, suboptimal debulking operation, recurrence and chemoresistance. ITM2A loss and higher FIGO stage were independent factors for poor prognosis. Expression of ITM2A inhibited growth and induced G2/M cell cycle arrest by attenuating cdc2, cyclin B1, cdc25c and p-cdc2 (Thr 161). In vitro and in vivo experiments showed that ITM2A expression significantly reduced the paclitaxel and carboplatin IC50 and tumor mass after paclitaxel treatment. Conclusion. ITM2A is a new biomarker of poor prognosis in ovarian cancer. It is a novel tumor suppressor that induces cell cycle arrest, acts as a chemosensitizer, and has therapeutic potential for ovarian cancer. (C) 2015 Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/7197)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.